Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

preview_player
Показать описание
  1. PeerView Oncology
  2. Dr. Stephen Liu
  3. CME
  4. meded
  5. oncology
  6. TKI
Рекомендации по теме
Macrocyclic TKIs in 0:28:43

Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

TRIDENT-1: repotrectinib in 0:08:16

TRIDENT-1: repotrectinib in ROS1-positive NSCLC

ROS1 Biomarker Lung 0:02:20

ROS1 Biomarker Lung Cancer: What Does That Mean?

Selective, Potent, Different: 0:50:46

Selective, Potent, Different: Next-Generation ROS1 and TRK Inhibition in NSCLC and Other Tumors

3 ROS1 Biomarker 0:03:44

3 ROS1 Biomarker Treatments for You, Explained

Lyudmila Bazhenova, MD, 0:00:29

Lyudmila Bazhenova, MD, on the progress being made towards successfully sequencing ALK inhibitors

ROS1 Treatment Options: 0:03:26

ROS1 Treatment Options: Lorlatinib and Repotrectinib - 2022 Program: Targeted Therapies Forum

Professor Ben Solomon: 0:44:24

Professor Ben Solomon: “Brief history of TKIs and what the future holds for existing patients”

Mecanism of BCR-ABL 0:01:00

Mecanism of BCR-ABL Tyrosine Kinase Inhibitors & Philadelphia chromosome formation

RET fusion-positive NSCLC: 0:27:47

RET fusion-positive NSCLC: Delivering targeted treatment | Panel discussion

Junichi Takagi IPI 0:52:51

Junichi Takagi IPI Surfacing: Lasso-grafted Fc design platform offers receptor agonists/antagonists

Timing of Second 0:02:20

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

Can the Addition 1:05:29

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Improve Outcomes?

Protein Kinase Ontology 0:15:12

Protein Kinase Ontology (ProKino) - IDG Digital Tool Fest 2021

Repotrectinib could be 0:02:40

Repotrectinib could be effective for treating ROS1 positive NSCLC: TRIDENT-1 trial

Using the Power 1:01:44

Using the Power of Cryo-EM to Uncover Principles of Kinase Signalling at the Membrane

Mechanisms of ALK 0:22:46

Mechanisms of ALK Resistance & Implications for Treatment

WEBINAR: Radiometals in 1:11:58

WEBINAR: Radiometals in Theranostics Applications: Present and Future Perspectives

NYSCHP Monthly WebinarDrug 1:26:05

NYSCHP Monthly WebinarDrug Approvals Update - Focus on 2022

Towards decision support 0:30:48

Towards decision support for treatment of lungworm infections in grazing cattle

AAMDSIF 40th Anniversary 1:07:30

AAMDSIF 40th Anniversary Summit: Advances in the Science and Treatment of PNH

Book of YouTube 0:05:53

Book of YouTube Topics for All Categories in Hindi | How to Find Daily YouTube Topics

GRACE Targeted Therapies 0:22:49

GRACE Targeted Therapies Lung Cancer 2021 - Management of Uncommon EGFR Mutations Including EXON 20

Time for Even 0:58:24

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC